Huperzine A

Highly selective, reversible, BBB-penetrant AChE inhibitor extracted from Chinese club moss — 25-100× more potent than donepezil per mg and one of the most potent natural cholinesterase inhibitors known. A-tier evidence in Chinese Alzheimer's RCTs (Xu 1995 keystone, Zhang 2002, Cochrane 2008 pooled) at 200-400 mcg/day showing replicated MMSE / ADAS-Cog improvement. Unusually long pharmacodynamic half-life (~12 hr) for an AChE inhibitor — single dose covers most of a waking day, but chronic accumulation drives muscarinic + nicotinic post-synaptic downregulation (the "cholinergic tolerance" pattern). Cycling 4 weeks on / 1-2 weeks off is non-negotiable, not optional. For Dylan: OPTIONAL-ADD as a PRN pre-cognitive-task booster (50-100 mcg, 1-2× per week max while citicoline runs daily), NOT a daily-default at 20. Stacking AChE inhibition on top of citicoline 500 mg is mechanistically real (more substrate + slower breakdown = bigger acetylcholine signal) but raises cholinergic excess risk (nausea, sweating, vivid dreams, mild bradycardia) and amplifies the long-half-life accumulation problem if used daily.

Huperzine A is a plant alkaloid isolated in 1986 by Chinese pharmacologists (Liu et al., Shanghai Institute of Materia Medica) from Huperzia serrata — known in traditional Chinese medicine as Qian Ceng Ta (千層塔, "thousand-layered pagoda") and used historically for fever, inflammation, and "memory weakness" in elderly. The (-)-enantiomer is the active form; the (+)-form is much weaker.

1. Highly selective reversible AChE inhibition (primary mechanism)

• AChE (acetylcholinesterase) is the enzyme that breaks down acetylcholine at the synaptic cleft, terminating the cholinergic signal. Inhibiting AChE = acetylcholine lingers longer = stronger and more sustained cholinergic signaling.
• Huperzine A binds AChE at the catalytic anionic site reversibly (unlike irreversible organophosphate AChE inhibitors like sarin, malathion, or the older generation drug metrifonate).
• Selectivity for AChE over BChE (butyrylcholinesterase) is ~1000:1 — vs donepezil ~400:1, galantamine ~50:1, tacrine ~10:1, rivastigmine ~0.5:1 (rivastigmine actually prefers BChE). High AChE selectivity matters because BChE inhibition drives most of the peripheral cholinergic side effects (GI, salivary, cardiac) without contributing much to the cognitive effect.
• Potency: IC50 ~30-80 nM at AChE. On a per-mg basis, huperzine A is ~25-100× more potent than donepezil, ~250× more potent than galantamine, and ~2000× more potent than tacrine. This is why the nootropic dose is in micrograms (50-200 mcg) while donepezil is dosed in milligrams (5-10 mg).

2. Long duration of action

• Half-life of huperzine A in plasma: ~10-14 hours (oral). For a reversible AChE inhibitor this is unusual — donepezil's plasma half-life is ~70 hours but its AChE inhibition normalizes within 24-48 hr; huperzine's pharmacodynamic AChE inhibition lasts ~6-8 hours, with measurable cholinergic effect persisting 12+ hours.
• Practical consequence: single morning dose covers a full waking day. Practical concern: daily dosing leads to accumulation across multiple half-lives → trough AChE inhibition stays elevated even before next dose → effectively continuous AChE inhibition → post-synaptic receptor adaptation.

3. NMDA receptor antagonism (secondary, dose-dependent)

• At doses above ~200 mcg, huperzine A weakly antagonizes the NMDA glutamate receptor at the ion channel pore. Affinity is ~25 μM (much weaker than memantine ~1 μM), but at supratherapeutic doses (300-400 mcg) this contributes meaningfully to the proposed neuroprotective effect against glutamate excitotoxicity.
• This is the basis for the DARPA / US Air Force interest in huperzine A as a prophylactic against organophosphate nerve agent exposure (sarin, VX, soman): by occupying AChE reversibly before nerve agent exposure, huperzine A prevents the irreversible nerve agent from binding and being lethal. Pre-treatment with huperzine A 200 mcg has been studied as a battlefield prophylactic — animal data supports a 6-8 hr protective window.

4. Mitochondrial / antioxidant effects (animal data)

• Animal models show huperzine A reduces oxidative stress markers, preserves mitochondrial membrane potential under hypoxia/ischemia, and reduces β-amyloid-induced neuronal death in primary cortical cultures. These effects are at supraphysiological concentrations and translation to oral dosing is uncertain.

5. Why "AChE inhibitor on top of choline donor" is a real mechanism question for Dylan

• Citicoline (Dylan's V4) → free choline elevation → more substrate for choline acetyltransferase (ChAT) → more acetylcholine synthesized.
• Huperzine A → AChE inhibition → acetylcholine broken down more slowly at the synapse.
• These mechanisms are complementary, not redundant — synthesis-side + clearance-side. Stack should produce a larger and longer cholinergic signal than either alone.
• Risk: chronic strong cholinergic signaling → muscarinic M1/M3 + nicotinic α4β2/α7 post-synaptic receptor downregulation → tolerance + on-stopping rebound dysphoria. The classic "I felt great for 3 weeks, then it stopped working and I felt flat for 2 weeks after stopping" pattern.
• This is exactly why cycling matters more for huperzine + citicoline than for citicoline alone.